These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 24417802)

  • 1. Intrathecal immune reset in multiple sclerosis: exploring a new concept.
    Bonnan M
    Med Hypotheses; 2014 Mar; 82(3):300-9. PubMed ID: 24417802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Meningeal tertiary lymphoid organs: Major actors in intrathecal autoimmunity].
    Bonnan M
    Rev Neurol (Paris); 2015 Jan; 171(1):65-74. PubMed ID: 25555848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does disease-irrelevant intrathecal synthesis in multiple sclerosis make sense in the light of tertiary lymphoid organs?
    Bonnan M
    Front Neurol; 2014; 5():27. PubMed ID: 24653716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compartmentalization of inflammation in the CNS: a major mechanism driving progressive multiple sclerosis.
    Meinl E; Krumbholz M; Derfuss T; Junker A; Hohlfeld R
    J Neurol Sci; 2008 Nov; 274(1-2):42-4. PubMed ID: 18715571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
    Studer V; Rossi S; Motta C; Buttari F; Centonze D
    J Neuroimmunol; 2014 Nov; 276(1-2):229-31. PubMed ID: 25175066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of disease duration, clinical course, and immunosuppressive therapy on the synthesis of intrathecal oligoclonal IgG bands in multiple sclerosis.
    Axelsson M; Mattsson N; Malmeström C; Zetterberg H; Lycke J
    J Neuroimmunol; 2013 Nov; 264(1-2):100-5. PubMed ID: 24125567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments.
    Bonnan M
    Mult Scler Int; 2015; 2015():296184. PubMed ID: 25653878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrathecal EBV antibodies are part of the polyspecific immune response in multiple sclerosis.
    Otto C; Oltmann A; Stein A; Frenzel K; Schroeter J; Habbel P; Gärtner B; Hofmann J; Ruprecht K
    Neurology; 2011 Apr; 76(15):1316-21. PubMed ID: 21482946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis.
    Perissinotti AJ; Reeves DJ
    Ann Pharmacother; 2010 Oct; 44(10):1633-40. PubMed ID: 20807868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging monoclonal antibody therapies for multiple sclerosis.
    Cree B
    Neurologist; 2006 Jul; 12(4):171-8. PubMed ID: 16832236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paediatric and adult multiple sclerosis: age-related differences and time course of the neuroimmunological response in cerebrospinal fluid.
    Reiber H; Teut M; Pohl D; Rostasy KM; Hanefeld F
    Mult Scler; 2009 Dec; 15(12):1466-80. PubMed ID: 19995844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligoclonal bands and antibody responses in multiple sclerosis.
    Correale J; de los Milagros Bassani Molinas M
    J Neurol; 2002 Apr; 249(4):375-89. PubMed ID: 11967640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS.
    Villar LM; Sádaba MC; Roldán E; Masjuan J; González-Porqué P; Villarrubia N; Espiño M; García-Trujillo JA; Bootello A; Alvarez-Cermeño JC
    J Clin Invest; 2005 Jan; 115(1):187-94. PubMed ID: 15630459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intrathecal oligoclonal and polyspecific immune response in multiple sclerosis].
    Robinson Agramonte MA; Reiber H; Dorta Contreras AJ; Hernández Díaz E
    Rev Neurol; 2001 Nov 1-15; 33(9):809-11. PubMed ID: 11784982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central role of JC virus-specific CD4+ lymphocytes in progressive multi-focal leucoencephalopathy-immune reconstitution inflammatory syndrome.
    Aly L; Yousef S; Schippling S; Jelcic I; Breiden P; Matschke J; Schulz R; Bofill-Mas S; Jones L; Demina V; Linnebank M; Ogg G; Girones R; Weber T; Sospedra M; Martin R
    Brain; 2011 Sep; 134(Pt 9):2687-702. PubMed ID: 21908874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.
    Krumbholz M; Theil D; Cepok S; Hemmer B; Kivisäkk P; Ransohoff RM; Hofbauer M; Farina C; Derfuss T; Hartle C; Newcombe J; Hohlfeld R; Meinl E
    Brain; 2006 Jan; 129(Pt 1):200-11. PubMed ID: 16280350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapeutic options for multiple sclerosis.
    Curtin F; Hartung HP
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):91-104. PubMed ID: 24325127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Established and novel disease-modifying treatments in multiple sclerosis.
    Cross AH; Naismith RT
    J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple sclerosis and Natalizumab.
    Fiore D
    Am J Ther; 2007; 14(6):555-60. PubMed ID: 18090880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.